Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Int J Cancer. 2013 Jan 15;132(2):251-8. doi: 10.1002/ijc.27696. Epub 2012 Jul 14.
The RAS-association domain family, commonly referred to as RASSF, is a family of 10 members (RASSF1-10) implicated in a variety of key biological processes, including cell cycle regulation, apoptosis and microtubule stability. Furthermore, RASSFs have been implicated in tumorigenesis and several family members are now thought to be tumor suppressors. As opposed to the KRAS oncogene, for which mutational activation is frequent in colorectal cancer (CRC), RASSFs are found to be silenced mainly by aberrant promoter methylation. In particular, RASSF1A, RASSF2 and RASSF5 methylation has been associated with CRC development, though the mechanisms of action remain poorly understood. This review focus on the current knowledge of RASSF inactivation in CRC, particularly RASSF1A, and on the implications RASSFs may have as potential biomarkers and for the development of new targeted therapies for CRC.
RAS 相关结构域家族，通常称为 RASSF，是一个由 10 个成员（RASSF1-10）组成的家族，涉及多种关键的生物学过程，包括细胞周期调控、细胞凋亡和微管稳定性。此外，RASSF 还与肿瘤发生有关，现在认为几个家族成员是肿瘤抑制因子。与 KRAS 癌基因不同，KRAS 癌基因在结直肠癌（CRC）中经常发生突变激活，而 RASSF 主要通过异常启动子甲基化失活。特别是，RASSF1A、RASSF2 和 RASSF5 的甲基化与 CRC 的发生发展有关，但作用机制尚不清楚。这篇综述主要关注 RASSF 在 CRC 中的失活，特别是 RASSF1A，以及 RASSF 作为潜在生物标志物和开发 CRC 新的靶向治疗方法的意义。
